Ontology highlight
ABSTRACT:
SUBMITTER: Adams RL
PROVIDER: S-EPMC3629757 | biostudies-literature | 2013 Apr
REPOSITORIES: biostudies-literature
Adams Rebecca L C RL Bird Robert J RJ
Therapeutic advances in hematology 20130401 2
Deferasirox is an orally administered, once-daily iron chelator with a generally good safety and efficacy profile. Reported adverse events in the older myelodysplastic population are somewhat different to the more intensively investigated and younger thalassaemic population. Renal impairment is the most concerning adverse event, but this is reversible if identified and the drug is withdrawn early. Gastrointestinal effects, particularly diarrhoea, can be troublesome for older patients, but can be ...[more]